EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR ‐ TKI Resistance

Jingyi Wu, Xiangfei Wu, Jing Wang, Guili Feng, Yuhan Wang, Zide Chen, Wei Wang, Rong Wang iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jingyi Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Brain Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanfang Hospital, Natural Science Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐small cell lung cancer patients with EGFR mutation have a high rate of brain metastases, and EGFR tyrosine kinase inhibitors (TKIs) are the principal therapeutic approach. However, acquired targeted therapy resistance is the main reason for EGFR‐TKIs' treatment failure. At present, the mechanism of intracranial acquired targeted therapy resistance is limited, mainly due to the lack of a cell line that can be used for its study.

Methods

A brain parenchymal metastatic sample that progressed after third‐generation EGFR‐TKI treatment was used to establish a cell line named AlmoR1. The genetic characteristics of the cell line were evaluated by short tandem repeat (STR) profiling and whole‐exome sequencing analysis. The phenotypic characteristics were characterized by CCK8, western blot, HE staining, immunohistochemistry (IHC), and orthotopic brain tumor model.

Results

The cell line we successfully established, AlmoR1, can be passed in vitro stably. STR analysis revealed it was a novel NSCLC BM cell line. It harbors the EGFR E746_A750del (ex19del) mutation, and the IC50 to almonertinib and osimertinib of AlmoR1 was significantly higher than that of sensitive cells. In our orthotopic brain tumor model construction with AlmoR1 cells, 75% (3/4) tumor formation can be observed in the living system.

Conclusions

These data suggest that the established cell line, AlmoR1, preserved the resistance to broad third‐generation EGFR‐TKIs and good tumorigenicity in an intracranial orthotopic model, so that it can serve as a new tool to elucidate the pathogenesis, explore new treatment methods, and conduct the development of new drugs for targeted therapy resistance of brain metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsBrain NeoplasmsProtein Kinase InhibitorsHumansErbB ReceptorsAnimalsMiceCell Line, TumorMutationXenograft Model Antitumor AssaysMaleFemale

Stichwörter der Autor:innen

AlmoR1NSCLCbrain metastasisprimary culturethe resistance of third‐generation EGFR‐TKIs

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
  • Department of Neurosurgery, Guangdong Sanjiu Brain Hospital, Guangzhou, Guangdong, People's Republic of China.
  • Department of Interventional Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, People's Republic of China.

ORCID-Profile: Rong Wang

Förderung

  • Nanfang Hospital
  • Natural Science Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Wu, J., Wu, X., Wang, J., Feng, G., Wang, Y., Chen, Z., Wang, W., & Wang, R. (2025). Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR ‐ TKI Resistance. Cancer Medicine. https://doi.org/10.1002/cam4.70827

Vancouver

Wu J, Wu X, Wang J, Feng G, Wang Y, Chen Z, et al. Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR ‐ TKI Resistance. Cancer Medicine. 2025. doi:10.1002/cam4.70827

BibTeX
@article{Wu2025,
  author = {Wu, Jingyi and Wu, Xiangfei and Wang, Jing and Feng, Guili and Wang, Yuhan and Chen, Zide and Wang, Wei and Wang, Rong},
  title = {Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR ‐ TKI Resistance},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70827}
}
Kostenlos starten →